2-methyltryptoline has been researched along with Parkinson Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Collins, MA; Neafsey, EJ | 1 |
| Hansen, S; Jones, K; Perry, TL; Wall, RA | 1 |
2 other study(ies) available for 2-methyltryptoline and Parkinson Disease
| Article | Year |
|---|---|
Beta-carboline analogues of N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP): endogenous factors underlying idiopathic parkinsonism?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Aotus trivirgatus; Carbolines; Caudate Nucleus; Dopamine; Homovanillic Acid; Hydroxyindoleacetic Acid; Indoles; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Serotonin; Substantia Nigra | 1985 |
4-phenylpyridine and three other analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine lack dopaminergic nigrostriatal neurotoxicity in mice and marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callitrichinae; Carbolines; Corpus Striatum; Dopamine; Isoquinolines; Male; Mice; Mice, Inbred C57BL; Parkinson Disease; Pyridines; Substantia Nigra; Tetrahydroisoquinolines | 1987 |